Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours.
|
30819233 |
2019 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Genomic high-resolution profiling of single CKpos/CD45neg flow-sorting purified circulating tumor cells from patients with metastatic breast cancer.
|
25267515 |
2014 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Cyclin D1-dependent induction of luminal inflammatory breast tumors by activated notch3.
|
23928992 |
2013 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Fluorescent in-situ hybridization was performed on a tissue microarray of 495 breast tumors (74% of patients) to measure CCND1 and RSF1 copy number.
|
24367492 |
2013 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
High cyclin D1 expression statistically significantly correlated with lower tumor grade, estrogen and progesterone receptor positivity and lower proliferation activity in breast tumors and increased breast cancer-specific survival and overall survival.
|
23336272 |
2013 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Cell cycle regulators cyclin D1 and CDK4/6 have estrogen receptor-dependent divergent functions in breast cancer migration and stem cell-like activity.
|
23839043 |
2013 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
A set containing 281 CCND1-non-amplified breast tumours was used for comparisons.
|
22002566 |
2012 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The results obtained suggest that the increment of the levels of cyclin D1 in intra-ductal breast tumors in older woman that we have examined is significantly associated with a lower proliferation rate.
|
22231956 |
2012 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
CCND1 was amplified in 4% of BRCA1-associated, 13% of BRCA2-associated and 21% of non-BRCA1/BRCA2 breast tumors (P = 0.054).
|
21327470 |
2011 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers.
|
19636701 |
2010 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response.
|
20948315 |
2010 |
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Subgroup analysis showed associations between carriers of the E2F2_-5368_G allele (OR: 0.60, 95% CI: 0.42-0.85), carriers of the CCND1_870_G allele (OR: 0.66, 95% CI: 0.45-0.96) and carriers of the CCND3_-677_T allele (OR: 1.72, 95% CI: 1.20-2.49) and HER2 expression in breast tumors.
|
19142864 |
2009 |
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.
|
19124506 |
2009 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer.
|
18240019 |
2009 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists.
|
18632615 |
2008 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer.
|
18456656 |
2008 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
The helix-loop-helix protein Id1 requires cyclin D1 to promote the proliferation of mammary epithelial cell acini.
|
18413773 |
2008 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Herein, levels of the miR-17-5p/miR-20a miRNA cluster were inversely correlated to cyclin D1 abundance in human breast tumors and cell lines.
|
18695042 |
2008 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Heregulin beta1 promotes breast cancer cell proliferation through Rac/ERK-dependent induction of cyclin D1 and p21Cip1.
|
17941827 |
2008 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy.
|
18347178 |
2008 |
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Tumor susceptibility and prognosis of breast cancer associated with the G870A polymorphism of CCND1.
|
18043898 |
2008 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome.
|
17653856 |
2008 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
These results strongly suggest that daintain/AIF-1 can promote the growth of breast tumors via activating NF-kappaB signaling, which consequently up-regulates the expression of cyclin D1, implying that daintain/AIF-1 may be a novel target molecule for the prognosis and therapy of breast cancer.
|
18341653 |
2008 |
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases.
|
18237245 |
2008 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to CYCLIN D1 promoter via activation of Stat3.
|
17344214 |
2007 |